Fortrea Inc.

12 days ago · globenewswire.com

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.

12 days ago · globenewswire.com

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

20 days ago · benzinga.com

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.

20 days ago · globenewswire.com

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

2 months ago · zacks.com

Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · zacks.com

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

2 months ago · zacks.com

Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

2 months ago · seekingalpha.com

Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.

2 months ago · zacks.com

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago.